Download MendeleyDiscovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine beta-Lactamases.
Durand-Reville, T.F., Comita-Prevoir, J., Zhang, J., Wu, X., May-Dracka, T.L., Romero, J.A.C., Wu, F., Chen, A., Shapiro, A.B., Carter, N.M., McLeod, S.M., Giacobbe, R.A., Verheijen, J.C., Lahiri, S.D., Sacco, M.D., Chen, Y., O'Donnell, J.P., Miller, A.A., Mueller, J.P., Tommasi, R.A.(2020) J Med Chem 63: 12511-12525
- PubMed: 32658473
- DOI: https://doi.org/10.1021/acs.jmedchem.0c00579
- Primary Citation of Related Structures:
6VHS - PubMed Abstract:
Multidrug resistant Gram-negative bacterial infections are an increasing public health threat due to rapidly rising resistance toward β-lactam antibiotics. The hydrolytic enzymes called β-lactamases are responsible for a large proportion of the resistance phenotype. β-Lactamase inhibitors (BLIs) can be administered in combination with β-lactam antibiotics to negate the action of the β-lactamases, thereby restoring activity of the β-lactam. Newly developed BLIs offer some advantage over older BLIs in terms of enzymatic spectrum but are limited to the intravenous route of administration. Reported here is a novel, orally bioavailable diazabicyclooctane (DBO) β-lactamase inhibitor. This new DBO, ETX1317, contains an endocyclic carbon-carbon double bond and a fluoroacetate activating group and exhibits broad spectrum activity against class A, C, and D serine β-lactamases. The ester prodrug of ETX1317, ETX0282, is orally bioavailable and, in combination with cefpodoxime proxetil, is currently in development as an oral therapy for multidrug resistant and carbapenem-resistant Enterobacterales infections.
Organizational Affiliation:
Entasis Therapeutics, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
